Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03836001 · ClinicalTrials.gov registry record · Phase 2
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
A Phase 2 study of Epidermolysis Bullosa, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03836001: Completed Phase 2 study of Epidermolysis Bullosa, sponsored by Stanford University.
NCT03836001 is a Phase 2 study of Epidermolysis Bullosa that has completed, run by Stanford University. The registered enrollment target is 28 participants, above the 17-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (65% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03836001, a Phase 2 study of Epidermolysis Bullosa, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
Primary Outcome
Participants will be asked to complete a daily itch diary with their average itch numeric rating scale (AI-NRS) over the past 24 hours. Score range: 0 to 10, higher scores mean more itching.
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG Serlopitant Tablet
Study Locations (1)
California
- Stanford University - Redwood City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-04-18 |
| Est. Completion | 2022-06-24 |
| Phase | Phase 2 |
What the finished NCT03836001 record still lists
NCT03836001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, above the 17-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03836001 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03836001 about?
NCT03836001 is a clinical study titled "A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa". To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.
What is the current status of trial NCT03836001?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2019-04-18. Estimated completion is 2022-06-24.
What conditions does trial NCT03836001 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa.
What interventions are being tested in trial NCT03836001?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Serlopitant Tablet (DRUG).
Who is sponsoring clinical trial NCT03836001?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03836001 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03836001's enrollment target sits among peer trials
28 3rd of 10 higher than 8 of 10 other Epidermolysis Bullosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epidermolysis Bullosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
-
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
COMPLETED · Phase 2
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
ACTIVE NOT RECRUITING · Phase 3
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI